LEO LUZNIK to Tissue Donors
This is a "connection" page, showing publications LEO LUZNIK has written about Tissue Donors.
Connection Strength
2.063
-
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017 02; 102(2):391-400.
Score: 0.400
-
How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. Blood. 2023 01 05; 141(1):49-59.
Score: 0.154
-
Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control. 2002 Mar-Apr; 9(2):123-37.
Score: 0.145
-
HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv. 2019 09 10; 3(17):2581-2585.
Score: 0.122
-
Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. Biol Blood Marrow Transplant. 2018 05; 24(5):1099-1102.
Score: 0.110
-
The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2018 05; 53(5):521-534.
Score: 0.109
-
Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2017 Apr; 23(4):612-617.
Score: 0.101
-
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol. 2016 Apr 12; 9:35.
Score: 0.096
-
Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood. 2016 Jan 21; 127(3):352-9.
Score: 0.094
-
Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. Biol Blood Marrow Transplant. 2016 Jan; 22(1):112-8.
Score: 0.093
-
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. J Clin Oncol. 2015 Oct 01; 33(28):3152-61.
Score: 0.092
-
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015 Aug 20; 126(8):1033-40.
Score: 0.091
-
Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. Semin Hematol. 2015 Jul; 52(3):232-42.
Score: 0.090
-
Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood. 2014 Sep 25; 124(13):2131-41.
Score: 0.086
-
HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012 Nov 22; 120(22):4285-91.
Score: 0.075
-
Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood. 2007 May 15; 109(10):4564-74.
Score: 0.051
-
Nonmyeloablative alternative donor transplants. Curr Opin Oncol. 2003 Mar; 15(2):121-6.
Score: 0.039
-
Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. Bone Marrow Transplant. 2020 01; 55(1):40-47.
Score: 0.030
-
Activated Allogeneic Donor-derived Marrow-infiltrating Lymphocytes Display Measurable In Vitro Antitumor Activity. J Immunother. 2019 04; 42(3):73-80.
Score: 0.030
-
T Cell Repertoire Evolution after Allogeneic Bone Marrow Transplantation: An Organizational Perspective. Biol Blood Marrow Transplant. 2019 05; 25(5):868-882.
Score: 0.029
-
Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1887-1894.
Score: 0.026